Chen SK, et al. - In this cohort study, experts identified 11,248 propensity score-matched sets of people with RA aged ≥ 18 years with ≥ 2 RA diagnoses who started treatment with abatacept and tumor necrosis factor inhibitor (TNFi) in order to assess the relative risk of hospitalized infection among individuals with RA. Lower risk of hospitalized infection following the beginning of abatacept vs TNFi, which was driven chiefly by infliximab, was noted in this large cohort study of the RA individuals who began treatment with abatacept or TNFi as a first- or second-line biologic agent.